Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 vs Cyclosporine in Primary Membranous Nephropathy
NCT05862233Phase 3Active, not recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Jun 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Bejescin in primary membranous nephropathy (PMN), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Started Jun 2023; status: active, not recruiting.
02
Drugs
Bejescin
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05862233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862233.